Simple linear model provides highly accurate genotypic predictions of HIV-1 drug resistance

Antiviral Therapy

Volumn 9, Issue 3, 2004, Pages 343-352

  Wang, Kai ^a   Jenwitheesuk, Ekachai ^a   Samudrala, Ram ^a   Mittler, John E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DATA BASE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LINEAR REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; STATISTICAL MODEL; VIROLOGY;

ALGORITHMS; DATABASES, GENETIC; DRUG RESISTANCE, VIRAL; FORECASTING; GENOTYPE; HIV PROTEASE INHIBITORS; HIV-1; LINEAR MODELS; MICROBIAL SENSITIVITY TESTS; POINT MUTATION; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 3042812835     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Menendez-Arias L. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends in Pharmacological Sciences 2002; 23:381-388.
2. Aslanzadeh J. HIV resistance testing: an update. Annals of Clinical & Laboratory Science 2002; 32:406-413.
3. Shafer RW, Kantor R & Gonzales MJ. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Reviews 2000; 2:211-228.
4. Shafer RW, Jung DR & Betts BJ. Immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. Nature Medicine 2000; 6:1290-1292.
5. Kantor R, Machekano R, Gonzales MJ, Dupnik K, Shapiro JM & Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Research 2001; 29:296-299.
6. Van Laethem K, De Luca A, Antinori A, Cingolani A, Perna CF & Vandamme AM. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antiviral Therapy 2002; 7:123-129.
7. Rousseau M-N, Vergne L, Montes B, Peeters M, Reynes J, Delaporte E & Segondy M. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2001; 26:36-43.
8. Reid C, Bassett R, Day S, Larder B, DeGruttola V & Winslow D. A dynamic rules-based interpretation system derived by an expert panel is predictive of virological failure. Antiviral Therapy 2002; 7:S91.
9. Sevin AD, DeGruttola V, Nijhuis M, Schapiro JM, Foulkes AS, Para MF & Boucher CAB. Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group. Journal of Infectious Diseases 2000; 182:59-67.
10. Wang D, DeGruttola V, Hammer S, Harrigan R, Larder B, Wegner S, Winslow D & Zazzi M. A collaborative HIV resistance response database initiative: predicting virological response using neural network models. Antiviral Therapy 2002; 7:S96.
11. Beerenwinkel N, Schmidt B, Walter H, Kaiser R, Lengauer T, Hoffmann D, Korn K & Selbig J. Quantitative phenotype prediction by support vector machines. Antiviral Therapy 2002; 7:S74.
12. Draghici S & Potter RB. Predicting HIV drug resistance with neural networks. Bioinformatics 2003; 19:98-107.
13. Wang W & Kollman PA. Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance. Proceedings of the National Academy of Sciences, USA 2001; 98:14937-14942.
14. Jenwitheesuk E & Samudrala R. Improved prediction of HIV-1 protease-inhibitor binding energies by molecular dynamics simulations. BMC Structural Biology 2003; 3:2.
15. King M, Kempf D, Isaacson J, Rode R, Brun S, Bernstein B, Calvez V, Cohen-Codar I, Guillevic E, Chauvin J & Sun E. Using classification trees to explore relationships between viral genotype and response to lopinavir/ritonavir-based regimens. Antiviral Therapy 2002; 7:S82.
16. Beerenwinkel N, Schmidt B, Walter H, Kaiser R, Lengauer T, Hoffmann D, Korn K & Selbig J. Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proceedings of the National Academy of Sciences, USA 2002; 99:8271-8276.
17. Braun P, Helm M, Ehret R, Schmidt B, Stürner K, Walter H, Hoehn C, Korn K & Knechten H. Predictive value of different drug resistance interpretation systems in therapy management of HIV-infected patients in daily routine. Antiviral Therapy 2002; 7:S77.
18. Zolopa A, Lazzeroni L, Rinehart A & Kuritzkes D. Accuracy, precision and consistency of expert HIV-1 genotype interpretation: an international comparison (The GUESS study). Antiviral Therapy 2002; 7:S97.
19. De Luca A, Cingolani A, Giambenedetto SD, Trotta MP, Baldini F, Rizzo MG, Bertoli A, Liuzzi G, Narciso P, Murri R, Ammassari A, Perno CF & Antinori A. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. Journal of Infectious Diseases 2003; 187:1934-1943.
20. Cheng Y-C & Prusoff WH. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical Pharmacology 1973; 22:3099-3108.
21. Qari SH, Respess R, Weinstock H, Beltrami EM, Hertogs K, Larder BA, Petropoulos CJ, Hellmann N & Heneine W. Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. Journal of Clinical Microbiology 2002; 40:31-35.
22. Wang K, Samudrala R & Mittler JE. Weak agreement between predictions of 'reduced susceptibility' from antivirogram and phenosense assays. Journal of Clinical Microbiology 2004; 42:2353-2354.
23. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clinical Microbiology Reviews 2002; 15:247-277.
24. Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, Bernstein BM, Japour AJ, Sun E & Rode RA. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. Journal of Virology 2001; 75:7462-7469.
25. Paulsen D, Liao Q, Fusco G, St Clair M, Shaefer M & Ross L. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia. AIDS Research & Human Retroviruses 2002; 18:1011-1019.
26. Parkin NT, Chappey C & Petropoulos CJ. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS 2003; 17:955-961.
27. Tisdale M, Kemp S, Parry N & Larder B. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences, USA 1993; 90:5653-5656.
28. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L & Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy 2000; 5:41-48.
29. Blower SM, Aschenbach AN, Gershengorn HB & Kahn JO. Predicting the unpredictable: transmission of drug-resistant HIV. Nature Medicine 2001; 7:1016-1020.
30. Wahl LM & Nowak MA. Adherence and drug resistance: predictions for therapy outcome. Proceedings of the Royal Society of London 2000; 267:835-843.
31. Bates M, Wrin T, Huang W, Petropoulos CJ & Hellmann N. Practical applications of viral fitness in clinical practice. Current Opinion on Infectious Diseases 2003; 16:11-18.